VANCOUVER, British Columbia and WARMINSTER, Pa. , Oct. 03, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of data at The Liver Meeting ® 2017 organized by the American...

Cash to Provide Significant Support for Arbutus to Fund HBV R&D Pipeline Roivant to Support Accelerating Development of Arbutus’ HBV Pipeline and Maximizing the Value of Arbutus’ LNP Assets VANCOUVER, British Columbia and WARMINSTER, Pa. , Oct....

VANCOUVER, British Columbia and WARMINSTER, Pa. , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the company will present a corporate overview and business update at the...

Detailed Data to be Presented at AASLD in October VANCOUVER, British Columbia and WARMINSTER, Pa. , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced topline results of the bi-weekly...

VANCOUVER, British Columbia and WARMINSTER, Pa. , Sept. 22, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of HBV data at the following scientific conferences....

Arbutus’ LNP Technology Further Validated with New Results Arbutus to Receive Single Digit Royalties on Sales of Patisiran VANCOUVER, British Columbia and WARMINSTER, Pa. , Sept. 20, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV)...

An Examination of the Rapidly Emerging field of mRNA Therapeutics in a Live Webinar hosted by the Nucleic Acid Drug Delivery Leader Arbutus Biopharma VANCOUVER, British Columbia and WARMINSTER, Pa. , Sept. 07, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading...

Two New Drug Candidates Nominated for Development ARB-1740 Development Update Company to Host a Corporate Update Conference Call Today at 4:30 PM ET VANCOUVER, British Columbia and WARMINSTER, Pa., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading...

VANCOUVER, British Columbia and WARMINSTER, Pa., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, August 3, 2017 at 1:30 PM...

Alexion Decision Driven by Strategic Review of R&D Activities Collaboration Enabled Further Optimization of LNP for Delivery of mRNA Arbutus Views LNP as a Potential Source of Significant Non-Dilutive Capital VANCOUVER, British Columbia and WARMINSTER, Pa., July 27, 2017 (GLOBE NEWSWIRE) -- Arbutus...